您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2017 - 07 - 04
点击次数: 0
所属职位: 合伙人
所属公司: 方源资本
个人简介:
钱晶(Dianna Qian)在过去的十几年里面,一直专注在医疗健康的几个不同领域。从麦肯锡的医疗组的核心成员,到外资药厂的并购和新产品策划,到医疗VC投资。最近几年,开始中晚期投资和跨国并购。 钱晶于1999年-2002年在波士顿咨询公司(BCG)工作,2002-2004年在美国宾夕法尼亚大学的Wharton商学院读MBA。后来的13年专注于医疗健康的不同领域,她首先在麦肯锡的美国和中国办公室专注医疗健康的咨询工作4年,接着是担任外资医药企业中国和亚太区高管,最近5年半先后在两家著名的基金工作,从事不同阶段的医疗投资,并参与了最近一轮方源资本三期基金20亿美元的融资。 钱晶于2012年加入富达亚洲风险投资(Fidelity Growth Capital Asia)作为其投资总监,专注于早期的医疗投资。2014年年初加入方源资本(FountainVest)担任董事,是医疗团队的核心管理层之一。加入富达之前,钱晶是勃林格殷格翰(BI)中国区的副总裁,负责业务发展(Business Development)与新产品规划(New Product Planning)两个部门。勃林格殷格翰(BI)是全球最大的15家医药公司之一,同时是生物制药的生产外包领域的全球是两大巨头之一。她专注于企业并购、产品许可转让。主要项目包括肿瘤、糖尿病、肾科、疼痛和非处方药物,对于医疗器械也有涉足。 从2005年到2008年的四年里面,钱晶任职于麦肯锡的上海和新泽西办公室,专注于医疗领域。作为项目经理,领导团队完成了药品、疫苗、医疗器械和分销等十多個项目, 服务的客户包括(GSK, J&J, Cardinal health, Schering Plough 等)。 钱晶是Bayhelix的成员。Bayhelix是中国医药研发行业领导者组成的最知名和最活跃的组织。
发布时间: 2017 - 07 - 04
点击次数: 0
所属职位: 董事长
所属公司: 方恩(天津)医药发展有限公司
个人简介:
□ MPH in Health Policy and Management from Harvard University □ MA in Health Care Administration from The Wharton School, University of Pennsylvania □ MD from Peking Union Medical College □ 20 years of experience in the Pharma industry □ Head of Global Safety Assessment and Clinical Drug Development at Sigma-Tau USA (largest pharmaceutical company in Italy) □ Vice President of Quintiles Transnational Corporation. □ Long time advisor for the CFDA □ New Drug Review Committee □ Member of grant review committee for the National Key Drug Development
发布时间: 2017 - 07 - 04
点击次数: 0
所属职位: 总监
所属公司: 汇桥资本LB医疗基金
个人简介:
Dr. Bin Li is the founder and CIO of ABG-LB Healthcare Fund and a partner of Ally Bridge Group, a global healthcare investment fund based in Hong Kong. Previously, he was a Managing Director and the Head of Greater China Healthcare Research at Morgan Stanley and led the coverage of Greater China healthcare industry. Since he moved to Morgan Stanley and established the healthcare research practice in Hong Kong in 2008, he had been ranked as the top analyst in China healthcare industry by the most widely recognized investor surveys. He was ranked No. 1 Asia Healthcare Analyst by the Institutional Investor (II) for seven consecutive years (2008-2014) and No.1 China Healthcare Analyst each year by II since the poll started in 2010 (2010-2014). He was also repeatedly ranked as No. 1 Asia Healthcare Analyst by all other independent investor surveys including Greenwich and Asiamoney. In addition, he was rated as No. 1 in Wall Street Journal's Best Asia Healthcare Analysts poll for his stock selection in 2010. Before joining Morgan Stanley, he was a senior healthcare research analyst at Merrill Lynch (Hong Kong) and responsible for the firm’s stock research efforts on Asia healthcare. Before moving to Hong Kong in 2007, he was a key member of a top-rank US pharmaceutical research team at Merrill Lynch based in New York. Dr. Li has over 20-year experience in healthcare industry. He received his Ph.D. in biochemistry and MBA from New York University and bachelor degree from Fudan University, China. Prior to his sell-side career, he worked at Merck Research Laboratory as a scientist and published papers on peer-reviewed science journals.
发布时间: 2017 - 07 - 04
点击次数: 0
所属职位: 亚太创新中心高级总监
所属公司: 强生
个人简介:
亚太创新中心高级总监,强生
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务